232 related articles for article (PubMed ID: 21375467)
21. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy for severe combined immunodeficiencies.
Gaspar HB; Thrasher AJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
[TBL] [Abstract][Full Text] [Related]
23. Update on gene therapy for immunodeficiencies.
Kohn DB
Clin Immunol; 2010 May; 135(2):247-54. PubMed ID: 20071242
[TBL] [Abstract][Full Text] [Related]
24. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
Knight S; Collins M; Takeuchi Y
Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
[TBL] [Abstract][Full Text] [Related]
25. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy of inherited immunodeficiencies.
Santilli G; Thornhill SI; Kinnon C; Thrasher AJ
Expert Opin Biol Ther; 2008 Apr; 8(4):397-407. PubMed ID: 18352845
[TBL] [Abstract][Full Text] [Related]
27. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for primary immunodeficiencies: Part 1.
Cavazzana-Calvo M; Fischer A; Hacein-Bey-Abina S; Aiuti A
Curr Opin Immunol; 2012 Oct; 24(5):580-4. PubMed ID: 22981681
[TBL] [Abstract][Full Text] [Related]
29. Retroviral vector interactions with hematopoietic cells.
Everson EM; Trobridge GD
Curr Opin Virol; 2016 Dec; 21():41-46. PubMed ID: 27521874
[TBL] [Abstract][Full Text] [Related]
30. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia.
Kiem HP; Sellers S; Thomasson B; Morris JC; Tisdale JF; Horn PA; Hematti P; Adler R; Kuramoto K; Calmels B; Bonifacino A; Hu J; von Kalle C; Schmidt M; Sorrentino B; Nienhuis A; Blau CA; Andrews RG; Donahue RE; Dunbar CE
Mol Ther; 2004 Mar; 9(3):389-95. PubMed ID: 15006605
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
32. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.
Haviernik P; Bunting KD
Curr Gene Ther; 2004 Sep; 4(3):263-76. PubMed ID: 15384940
[TBL] [Abstract][Full Text] [Related]
33. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
34.
Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
[TBL] [Abstract][Full Text] [Related]
35. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell.
Biasco L; Ambrosi A; Pellin D; Bartholomae C; Brigida I; Roncarolo MG; Di Serio C; von Kalle C; Schmidt M; Aiuti A
EMBO Mol Med; 2011 Feb; 3(2):89-101. PubMed ID: 21243617
[TBL] [Abstract][Full Text] [Related]
36. Reducing the genotoxic potential of retroviral vectors.
Ramezani A; Hawley TS; Hawley RG
Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
[TBL] [Abstract][Full Text] [Related]
37. [Safety of retroviral vectors in gene therapy].
Bogoslovskaia EV; Glazkova DV; Shipulin GA; Pokrovskiĭ VV
Vestn Ross Akad Med Nauk; 2012; (10):55-61. PubMed ID: 23240501
[TBL] [Abstract][Full Text] [Related]
38. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
39. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
[TBL] [Abstract][Full Text] [Related]
40. [Development of gene therapy for hematopoietic stem cell using viral vectors].
Dong WJ; Zu ZX; Liu DP; Liang CC
Yi Chuan Xue Bao; 2003 Apr; 30(4):382-8. PubMed ID: 12812066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
